You searched for "fovea"
Uveal melanoma
3 August 2023
| Mertcan Sevgi, Timothy Beckman, Paul Cauchi, Julie Connolly, Vikas Chadha
|
EYE - Pathology, EYE - Oncology, EYE - Imaging
Uveal melanoma is the most common primary intraocular tumour. However, they are still rare, with an incidence of 2-8 per million [1]. The presence of a choroidal naevus is a risk factor for uveal melanoma [1]. Patients with choroidal lesions...
RCOphth Annual Congress - Day 3
25 May 2022
| Chris Henson
Follow live updates and key highlights from Day 3 of the RCOphth Annual Congress.
Retinoblastoma risk factors for recurrence
This study evaluates risk factors for local tumour recurrence of main solid tumour, subretinal seed, vitreous seed and new tumour formation in eyes with retinoblastoma (RB) management with primary chemotherapy over 20 years of follow-up. The study included 960 eyes...
Risk factors for NTG in a young Korean population
1 April 2015
| Anjali Gupta
|
EYE - Glaucoma
Previously known ocular and systemic risk factors for normal tension glaucoma (NTG) include myopia, peripapillary atrophy, disc haemorrhage, migraine, obstructive sleep apnoea, thyroid disease and cerebral infarction. However, most NTG risk factor studies have examined patients aged 40 years and...
Part 2: the Arclight Device: frugal imaging for eyecare
3 June 2024
| Andrew Blaikie, Sahib Tuteja, Gatera Fiston Kitema
|
EYE - General
In this three-part series (Click here for Part 1 and here for Part 3) Andrew Blaikie and his team explore the role and application of the Arclight Device in Imaging of the Eye. There are many different types of ophthalmic...
Intravitreal afibercept and ranibizumab for PCV
1 August 2016
| Efrosini Papagiannuli
|
EYE - Vitreo-Retinal
This is a retrospective, interventional series comprising 98 eyes with polypidal choroidal vasculopathy (PCV) with the aim of comparing treatments with afibercept and ranibizumab, highlighting any differences in their efficacy. Case notes and imaging (FFA / ICG / OCT) were...
RaScaL Study
1 June 2015
| Sofia Rokerya
|
EYE - Vitreo-Retinal
The RaScaL study was a six month, single-centre, controlled, prospective phase I/II study in which subjects with diabetic macular oedema (DME) and associated peripheral nonperfusion on ultrawide-field fluorescein angiography (UWFA) were randomised to: (1) study arm: ranibizumab (0.5 mg) injection...
Displacement of submacular haemorrhage – comparative study pneumatic displacement versus subretinal cocktail injection
3 October 2024
| Sofia Rokerya
|
EYE - Vitreo-Retinal
The authors report a multicentre retrospective interventional case series study comparing the outcome of submacular haemorrhage (SMH) using pneumatic displacement with intravitreal expansile gas versus treatment with pars plana vitrectomy (PPV) versus subretinal injection of tissue plasminogen activator (tPA), anti-vascular...
The butterfly effect
2 December 2019
| Gwyn Samuel Williams
|
EYE - General
One of the most fascinating aspects of being a consultant is seeing the workings of the machine that is medical training from the other side. For two years now I have taken part in the specialty recruitment interviews and it...
The management of chronic central serous chorioretinopathy
1 February 2017
| Marten E Brelen
|
EYE - Vitreo-Retinal
Central serous chorioretinopathy (CSCR) is a common retinal disease characterised by one or more serous neurosensory detachments. Patients present with acute onset blurring of vision, metamorphopsia and / or central scotomas. The condition is six times more common in men...
Pigmented paravenous retinochoroidal atrophy
4 December 2024
| William Spackman, Tun Giap Tan, Stephen Turner
|
EYE - Imaging, EYE - Vitreo-Retinal
Presentation A 46-year-old Caucasian female was referred to the eye clinic by her local optician following a routine sight test. She was noted to have pigmentary retinal changes in both eyes but was asymptomatic with no visual complaints. At presentation...
Myopia management
1 December 2022
| Shivam Goyal, Shona Redmond
|
EYE - General
With the growing prevalence of myopia at epidemic levels in some countries and increasing number of research publications on myopia control, there is a lot of controversy regarding the management of myopia. As none of them are at present available...
